Conservative Management of Placenta Accreta Spectrum
Surgical Conservative Management of Placenta Accreta Disorders
1 other identifier
interventional
36
1 country
1
Brief Summary
The resective-constructive surgery, detailed in prior research by Palacios-Jaraquemada JM, involves excising the placenta and its attachment on the myometrium, with modifications including the systematic use of a double JJ probe, omitting arterial ligation, and prioritizing careful dissection and reconstruction. A prospective single-center study conducted from January 4, 2020 to February 2, 2024, at the Tunisian maternity ward including cases of placenta accreta, increta and percreta. Data on the estimation of blood loss, complications, transfusions and intensive care admissions were recorded. Diagnosis of placenta accreta was based on imaging and histopathology. The blood loss calculation incorporates total blood volume and changes in hematocrit.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2020
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 4, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 17, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 30, 2024
CompletedFirst Submitted
Initial submission to the registry
February 2, 2024
CompletedFirst Posted
Study publicly available on registry
February 12, 2024
CompletedSeptember 19, 2024
September 1, 2024
2.6 years
February 2, 2024
September 3, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Estimated blood loss
Blood spoliation during procedure
peroperatively
Hemoglobin variation
The difference between the Baseline concentration of Hemoglobin and the lowest hemoglobin concentration noted during the procedure
First 24 hours]
Transfusion requirements
Number of red blood cells units transfused
First 24 hours
Procedure duration
Time needed to perform surgery from incision to skin closure
peroperatively
Intensive care transfer rate
Intensive care transfer following surgery for placenta accreta
first 24 hours
Secondary Outcomes (4)
Length of stay in ICU
time from surgery up to 30 days postoperative
Clotting disorders
time from surgery up to 30 days postoperative
Bladder wound
Time from surgery up to 30 days postoperative
Digestive wound
Time from surgery up to 30 days postoperative
Study Arms (3)
conservative surgery
EXPERIMENTALresective-constructive surgery: the excision of the placenta and its attachment site on the myometrium. Subsequently, uterine reconstruction is undertaken.
hysterectomy 1
ACTIVE COMPARATORStandard hysterectomy is performed
hysterectomy 2
ACTIVE COMPARATORStandard hysterectomy is performed
Interventions
The surgical procedure involved a midline incision for the laparotomy approach. Dissection of the uterus from the posterior bladder wall extended down to the cervix, with coagulation of the vesicouterine vessels. Hysterotomy was executed in the upper segment, just above the area of myometrial invasion. Hemostasis of the lower uterus was achieved through either square compression sutures or ligation of the colpouterine vessels. A conservative approach to uterine surgery was considered viable only under conditions of stable hemodynamics and when at least 2 cm of healthy myometrium was visibly intact above the cervix. For cases involving conservative resection, all myometrium affected by invasion and the entire placenta were excised. Subsequently, the uterus was reconstructed using a continuous stitching technique.
Eligibility Criteria
You may qualify if:
- All patients undergoing scheduled or emergency cesarean section for placenta accreta
You may not qualify if:
- No signs of Placenta Accreta Spectrum upon artificial delivery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tunis Universitylead
- University Tunis El Manarcollaborator
Study Sites (1)
Haithem Aloui
Manouba, Tunis Governorate, 2010, Tunisia
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Ben Marzouk Maghrebi, Professor
Tunis University Manar
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- university hospital assistant
Study Record Dates
First Submitted
February 2, 2024
First Posted
February 12, 2024
Study Start
January 4, 2020
Primary Completion
August 17, 2022
Study Completion
January 30, 2024
Last Updated
September 19, 2024
Record last verified: 2024-09